Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Equity Ratio (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Equity Ratio for 12 consecutive years, with 0.73 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio rose 241.85% year-over-year to 0.73, compared with a TTM value of 0.73 through Sep 2025, up 241.85%, and an annual FY2024 reading of 0.88, up 153.67% over the prior year.
  • Equity Ratio was 0.73 for Q3 2025 at Avalo Therapeutics, down from 0.83 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q1 2025 and bottomed at 0.91 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.21, with a median of 0.29 recorded in 2021.
  • The sharpest move saw Equity Ratio skyrocketed 1004.75% in 2023, then tumbled 425.91% in 2024.
  • Year by year, Equity Ratio stood at 0.29 in 2021, then tumbled by 213.68% to 0.33 in 2022, then surged by 206.36% to 0.35 in 2023, then surged by 153.67% to 0.88 in 2024, then dropped by 17.08% to 0.73 in 2025.
  • Business Quant data shows Equity Ratio for AVTX at 0.73 in Q3 2025, 0.83 in Q2 2025, and 0.89 in Q1 2025.